Prednimustine in adult acute myeloid leukaemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Acute myeloid leukemia (AML) is a significant health concern, particularly in elderly populations.
• Treatment options for AML in older adults often face challenges due to comorbidities and reduced tolerance to intensive therapies.

Purpose of the Study:

• To evaluate the efficacy and safety of Prednimustine as a single agent and in combination with vincristine for treating acute myeloid leukemia.
• To assess the tolerability and maintenance therapy outcomes of Prednimustine in AML patients.

Main Methods:

• A cohort of 23 elderly patients (≥64 years) received Prednimustine monotherapy (24-60 mg daily).
• A separate group of 14 patients (35-64 years) were treated with Prednimustine (60-80 mg daily) and vincristine (2.25 mg i.v. every 7-10 days).
• Maintenance therapy with Prednimustine (0-40 mg daily) was administered upon achieving remission.

Main Results:

• Four remissions (17%) were achieved with Prednimustine monotherapy in elderly patients.
• Six remissions (43%) were observed in the combination therapy group (Prednimustine + vincristine).
• No drug-induced pancytopenia was recorded prior to remission; maintenance therapy showed minimal side effects, with a median remission duration of 8 months.

Conclusions:

• Prednimustine exhibits low toxicity to normal bone marrow cells, highlighting its therapeutic value.
• The drug is particularly beneficial for elderly patients with AML, offering a potentially safer treatment alternative.
• Combination therapy with vincristine demonstrated a higher remission rate compared to monotherapy.